Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Harry Fisch, insider at Veru

Harry Fisch Insider Information

Director of Veru
Harry Fisch, M.D., F.A.C.S. is the Founder, Vice Chairman of the Board, and Chief Corporate Officer of Veru Inc. and has served as a director of the Company since October 2016. Dr. Fisch was the co-founder of Aspen Park and served as the Chairman of the Board and Chief Scientific Officer of Aspen Park from July 2014 to October 2016. From 1994 to 2016, Dr. Fisch served as the Chief Executive Officer and President of Millennium Sciences, Inc. Dr. Fisch has also had numerous academic and clinical appointments including Clinical Professor of Urology and Reproductive Medicine at Weill College of Medicine, Cornell University from 2009 to current, Director of the Male Reproductive Center at Albert Einstein College of Medicine/Montefiore Medical Center from 1998 to 1999 and Professor of Clinical Urology at Columbia University, College of Physicians and Surgeons from 1999 to 2009. From 2014 to 2015, Dr. Fisch hosted The Dr. Harry Fisch Show on Men’s Health on Howard Stern’s SiriusXM radio channel 101. Dr. Fisch is a Board Certified Urologist and a Fellow of the American College of Surgeons. Dr. Fisch holds a B.A. in Chemistry from the State University of New York at Binghamton, an M.D. from Mount Sinai School of Medicine, New York, and performed his surgical and urologic training at Albert Einstein College of Medicine/Montefiore Medical Center.

How old is Harry Fisch?

Dr. Fisch is currently 63 years old. There are 3 older executives and no younger executives at Veru. Learn More on Harry Fisch's age.

How do I contact Harry Fisch?

The corporate mailing address for Dr. Fisch and other Veru executives is 48 NW 25th Street Suite 102, Miami FL, 33127. Veru can also be reached via phone at (305) 509-6897 and via email at [email protected] Learn More on Harry Fisch's contact information.

Has Harry Fisch been buying or selling shares of Veru?

Harry Fisch has not been actively trading shares of Veru in the last ninety days. As an example of a recent trade by , on Sunday, May 22nd, 0 shares of BMO Capital Markets stock. Learn More on Harry Fisch's trading history.

Who are Veru's active insiders?

Veru's insider roster includes Harry Fisch (Director), and Lucy Lu (Director). Learn More on Veru's active insiders.

Are insiders buying or selling shares of Veru?

During the last year, Veru insiders bought shares 1 times. They purchased a total of 4,800 shares worth more than $32,544.00. During the last year, insiders at the sold shares 1 times. They sold a total of 100,000 shares worth more than $835,000.00. The most recent insider tranaction occured on August, 17th when Director Lucy Lu bought 4,800 shares worth more than $32,544.00. Insiders at Veru own 23.1 % of the company. Learn More about insider trades at Veru.

Information on this page was last updated on 8/17/2021.

Harry Fisch Insider Trading History at Veru

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2021Sell100,000$8.35$835,000.00View SEC Filing Icon  
8/26/2020Buy5,000$2.76$13,800.00View SEC Filing Icon  
2/21/2020Buy1,000$4.34$4,340.00View SEC Filing Icon  
9/3/2019Buy10,000$1.93$19,300.00View SEC Filing Icon  
8/29/2019Buy7,000$1.92$13,440.00View SEC Filing Icon  
3/15/2019Buy3,000$1.47$4,410.00View SEC Filing Icon  
3/13/2019Buy3,500$1.47$5,145.00View SEC Filing Icon  
3/5/2019Buy3,500$1.47$5,145.00View SEC Filing Icon  
2/26/2019Buy5,000$1.27$6,350.00View SEC Filing Icon  
2/21/2019Buy5,000$1.35$6,750.00View SEC Filing Icon  
2/19/2019Buy5,000$1.36$6,800.00View SEC Filing Icon  
2/15/2019Buy13,681$1.36$18,606.16View SEC Filing Icon  
12/18/2018Buy30,000$1.42$42,600.00View SEC Filing Icon  
3/16/2018Buy5,000$1.96$9,800.00View SEC Filing Icon  
3/14/2018Buy10,000$1.87$18,700.00View SEC Filing Icon  
3/12/2018Buy10,000$1.80$18,000.00View SEC Filing Icon  
3/9/2018Buy10,000$1.88$18,800.00View SEC Filing Icon  
3/7/2018Buy24,000$1.62$38,880.00View SEC Filing Icon  
9/13/2017Buy34,250$1.51$51,717.50View SEC Filing Icon  
5/30/2017Buy12,000$1.27$15,240.00View SEC Filing Icon  
5/24/2017Buy10,000$1.10$11,000.00View SEC Filing Icon  
5/22/2017Buy24,750$1.02$25,245.00View SEC Filing Icon  
See Full Table

Harry Fisch Buying and Selling Activity at Veru

This chart shows Harry Fisch's buying and selling at Veru by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Veru Company Overview

Veru logo
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $13.38
Low: $12.66
High: $14.21

50 Day Range

MA: $9.08
Low: $4.35
High: $15.60

2 Week Range

Now: $13.38
Low: $4.34
High: $17.50

Volume

11,547,512 shs

Average Volume

24,788,880 shs

Market Capitalization

$1.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.